Diabetes – Page 6

Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease

11 months ago11 months ago talkbio0Tagged Cardiovascular system, Cessation of life, Chronic Kidney Diseases, Diabetes, Failure (biologic function), Kidney, Mortality Vital Statistics, Nordisk, Obesity, semaglutide, Wegovy

** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment

Eli Lilly Invests $5.3 Billion to Boost Production of Mounjaro and Zepbound

11 months ago11 months ago talkbio0Tagged Diabetes, Drug Industry, eli lilly, Investments, Manufacture, Mounjaro, Obesity, Weight Loss, Zepbound

** Eli Lilly, Mounjaro, Zepbound, Manufacturing, Investment, Diabetes, Obesity, Weight Loss, Pharmaceutical Industry

Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk

11 months ago talkbio0Tagged Administration occupational activities, Clinical Trials, Diabetes, Drug Industry, Eli Lilly, Insulin, insulin therapy, Nordisk, Primary Endpoint, trials, Weekly

Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.

Beyond Weight Loss: Wegovy’s Cardiovascular Benefits Uncovered in New Study

11 months ago talkbio0Tagged Administration occupational activities, Benefit, Cardiovascular system, Clinical Research, Diabetes, Glucagon-Like Peptide-1 Receptor, heart health, Obesity, Wegovy

Wegovy, cardiovascular benefits, weight loss, GLP-1 receptor agonist, heart health, obesity treatment, diabetes management, clinical study.

Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis

11 months ago talkbio0Tagged Analysis of substances, Cardiovascular Diseases, Diabetes, Long-term, Nordisk, Obesity, semaglutide, Wegovy, Weight Loss

Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.

Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management

12 months ago talkbio0Tagged Administration occupational activities, Biological Factors, Collaboration, Diabetes, Eli, Eli Lilly, GLUCOSE CONTROL, Innovent, Metabolic Diseases, next-generation therapy, Obesity, Phase 3 trials

Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.

Novo Nordisk Faces Scrutiny Over High Prices of Ozempic and Wegovy

12 months ago talkbio0Tagged Diabetes, Nordisk, Obesity, Prices, Sanders, Senator Bernie, Wegovy

Novo Nordisk, Ozempic, Wegovy, drug prices, Senator Bernie Sanders, diabetes, obesity

Senator Sanders Investigates Skyrocketing Costs of Novo Nordisk’s Diabetes and Weight Loss Drugs

12 months ago talkbio0Tagged Affordability, Diabetes, Evaluation, Health care facility, Nordisk, Novos, Prices, Senator Bernie Sanders, Wegovy

Senator Bernie Sanders, Novo Nordisk, diabetes, weight loss, drug prices, Novos Ozempic, Wegovy, investigation, healthcare costs, affordability

EMA Dispels Link Between GLP-1 Receptor Agonists and Suicidal Ideation Risk New

1 year ago talkbio0Tagged agonists, Continuous, Diabetes, Glucagon-Like Peptide-1 Receptor, Mental association, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, pharmacovigilance activities, Preventive monitoring, Suicidal ideation risk, Weight-Loss Agents

EMA, GLP-1 receptor agonists, Diabetes and weight-loss drugs, Suicidal ideation risk, No causal association, Pharmacovigilance activities, Continued monitoring